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Urticaria, defined by the presence of wheals and/or 
angio edema, is a common condition in children, promp-
ting parents to consult physicians. For its successful 
management, paediatric-specific features must be ta-
ken into account, regarding the identification of elicit-
ing triggers and pharmacological therapy. This review 
systematically discusses the current best-available evi-
dence on spontaneous acute and chronic urticaria as 
well as physical and other urticaria types in children. 
Potential underlying causes, namely infections, food and 
drug hypersensitivity, autoreactivity and autoimmune 
or other conditions, and eliciting stimuli are considered, 
with practical recommendations for specific diagnostic 
approaches. Second-generation antihistamines are the 
mainstay of pharmacological treatment aimed at relief of 
symptoms, which require dose adjustment for pae diatric 
use. Other therapeutic interventions are also discussed. 
In addition, unmet needs are highlighted, aiming to pro-
mote research into the paediatric population, ultimately 
aiming at the effective management of childhood urti-
caria. Key words: antihistamines; children; diagnosis; di-
sease management; pruritus; therapy; urticaria.
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Urticaria is subjectively recognized as a common pro-
blem in children. However, population-based studies are 
scarce. In a non-interventional birth cohort study, 5.4% 
of 404 participating 6-year-old children were reported 
to have had at least one episode of urticaria during the 
last year (1). Despite the fact that only half of the urti-
caria episodes were diagnosed by doctors, the authors 
report that this figure is in accordance with previously 
published data estimating overall urticaria frequency in 
children between 2.1% and 6.7%.
Childhood urticaria management is currently sug-
gested to be the same as in adults (2). However, there 
are paediatric-specific features that must be taken into 
account regarding eliciting triggers and pharmacologi-
cal therapy. This review systematically considers and 
discusses the currently best-available evidence on child-
hood urticaria addressing the diagnostic and therapeutic 
management. It also highlights unmet needs, aiming to 
promote research in this specific population.
Accurate diagnosis is an essential prerequisite to a 
successful management approach. Urticaria is defined 
by the presence of wheals and/or angioedema (3). A 
wheal comprises a central swelling, pruritus or burning 
sensation, disappearing within a maximum of 24 h, 
with out residual lesion (3). Angioedema is characterized 
by a swelling of the lower dermis and subcutis, asso-
ciated with a tingling sensation or pain, its resolution 
taking up to 72 h (3). Other diseases, including cuta-
neous mastocytosis, urticarial vasculitis or C1 esterase 
inhibitor deficiency, not fulfilling the aforementioned 
criteria for wheals and angioedema, are not considered 
in this review.
So far, no concise pathogenic mechanism has been 
identified for all cases of urticaria, although the activa-
tion and degranulation of basophils and/or mast cells 
leading to histamine release is a central feature sug-
gested to explain this troubling disease.
Urticaria management comprises 2 essential steps: the 
identification and elimination of eliciting triggers and/
or underlying causes and treatment aimed at providing 
symptom relief (2). 
ELICITING TRIGGERS AND UNDERLYING 
CAUSES IN CHILDHOOD URTICARIA
The avoidance/elimination of urticaria triggers or un-
derlying causes is the only potentially curative therapy. 
Therefore, it is the first concept in urticaria management 
in children (Table I). Comprehensive anamnesis and 
physical examination is the key for the identification 
of relevant eliciting factors. All extended diagnostic 
tests should be patient-tailored. Before ordering a test, 
especially regarding children, physicians must carefully 
consider the usefulness of its result. This should have 
a practical effect, ultimately allowing better disease 
management for the particular child.
Urticaria is classified into 4 main types according to 
its precipitants and duration: spontaneous acute urtica-
ria, spontaneous chronic urticaria, physical urticaria, 
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and other urticaria types (3). These different types dis-
play distinct underlying aetiologies, involving specific 
management approaches.
Spontaneous acute urticaria 
By definition, acute urticaria lasts less than 6 weeks 
(3). It is the most common type of urticaria in children 
(1, 4–6). In many cases of urticaria, no specific cause 
is found. Overall, success in identifying a cause in 
paediatric acute urticaria varies widely in literature, 
from approximately 20% to 90% (7, 8). This is mainly 
justified by different patient recruitment (e.g. from 
emergency departments, hospitalized or specialized 
units/departments), diagnostic testing performed, and 
criteria used for establishing a cause. The possibility that 
a specific combination of several triggers is required to 
elicit acute urticaria could be one explanation for why 
symptoms may never reappear. 
Infections, drug and food hypersensitivity have been 
reported as common potential triggers of acute urticaria 
in children.
Infections
Infections have been found to be the most frequently 
associated potential triggers in several studies (4, 8–11). 
Although the exact role and pathogenesis of mast cell 
activation by infectious processes remains unclear (12), 
there is no doubt for a causal relationship to infections 
in acute urticaria (13). Usually these are upper respi-
ratory tract infections, but gastrointestinal and urinary 
infections have also been implied (4, 7–11, 13). Viruses, 
such as adenovirus, enterovirus, rotavirus, respiratory 
syncytial virus, Epstein-Barr virus and cytomegalovirus 
have been reported to cause acute urticaria in children 
(8, 11, 13). Seasonalities of several acute respiratory 
viral infections and acute urticaria coincide, which un-
derlines the significance of these infections as a potential 
cause of acute urticaria in children (7, 13).
Bacteria, such as streptococcus, as well as My-
coplasma pneumoniae may induce urticaria in children 
(11, 13, 14). Parasitic infections, including Blastocystis 
hominis, Plasmodium falciparum and Anisakis simplex, 
may also induce urticaria (13, 15). Regarding the Ani-
sakis nematode, its role in recurrent acute urticaria is 
controversial (13). However, a paediatric case-control 
study involving 200 patients has found a significantly 
higher risk for relapsing acute urticaria in sensitized 
children (16). Fungi have not been stated as a cause of 
acute urticaria (13).
Infections are a potentially treatable cause of urti-
caria. However, the role of clinically silent infections 
in childhood urticaria is debatable. This issue requires 
case-control studies and follow-up of urticaria remission 
in response to infection-directed therapy.
Drug hypersensitivity
Drug hypersensitivity is the second main suspected 
cause in childhood acute urticaria (7, 8, 10, 11). The 
most commonly reported drugs are antibiotics and 
non-steroidal anti-inflammatory drugs (NSAIDs), 
which are often prescribed during infections. True drug 
hypersensitivity can be a cause of urticaria, implying 
drug suspension and, if necessary, the prescription of an 
alternative drug without cross-reactivity to the former. 
However, its role in acute urticaria in children may be 
overestimated. Studies evaluating > 40 children with 
a plausible history of drug allergy have demonstrated 
that > 90% of them were able to tolerate the suspected 
drug after a proper diagnostic work-up (17, 18). The 
confirmation of a drug hypersensitivity diagnosis may 
involve in vitro assays and/or skin tests and ultimately 
drug provocation tests, if not contraindicated, according 
to the patient’s history and implicated drug.
Food allergy
Despite the fact that acute urticaria is the main clinical 
manifestation in immunoglobulin E (IgE)-mediated 
food allergy, food allergens have been documented 
as a cause of less than 7% of all cases of urticaria in 
several studies (7, 10, 11). Nevertheless, food allergy 
was still the most frequent cause of acute urticaria in 
children referred to Allergology Departments in Spain. 
This probably did not reflect its frequency in the general 
population, due to paediatricians not referring those 
urticaria cases suspected of having an infectious cause 
to the specialists (5).
Food allergy may occur after direct skin contact 
(a form of contact urticaria), inhalation or ingestion. 
The prominent pathophysiological mechanism is IgE-
mediated, symptoms occurring immediately (in less 
than 1 h), most commonly after food ingestion. The 
diagnostic work-up mainly consists of allergen-specific 
IgE quantification with total IgE and/or skin-prick tes-
ting regarding the suspected food allergens. Oral food 
challenges are the gold standard for diagnosis (19).
If identified, the specific-food allergens need to be 
eliminated from the child’s diet. Avoidance of type I 
Table I. Key concepts in urticaria management in children
• Avoidance/elimination of underlying causes and/or eliciting triggers is 
important.
• Second-generation H1-antihistamines are the mainstay of 
pharmacological treatment aimed at providing symptom relief. 
Up-dosing has not been validated in children. First-generation H1-
antihistamines should be avoided, mostly due to relevant side-effects. 
• Difficult cases may require other therapeutic interventions, the risk–
benefit ratio being carefully analysed as there is hardly any evidence 
supporting it in children.
• Corticosteroids should be avoided whenever possible and strictly used 
for short periods only (3–7 days), given the unacceptable side-effects 
from long-term use.
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allergens is expected to induce remission of urticaria 
within less than 48 h (2). 
Practical recommendation: An extended diagnostic 
work-up is not needed in childhood acute urticaria. 
Specific testing should be performed only if strongly 
suggested by the patient’s history (Table II).
Spontaneous chronic urticaria
Chronic urticaria has a duration of > 6 weeks (3). 
Population-based studies are needed to estimate the fre-
quency of chronic urticaria in children. In a nationwide 
Spanish study, including patients treated by allergology 
specialists, urticaria was diagnosed in 66 out of 917 
children, of whom 12 (18%) were chronic (5). In another 
prospective study addressing all different childhood 
urticaria types evaluated in an Allergy Unit, chronic 
urticaria was diagnosed in 17 of 54 (32%) children (11).
Many suspected causes have been considered in 
childhood chronic spontaneous urticaria, including 
infections, autoreactivity, autoimmunity, food hyper-
sensitivity; and other precipitants.
Infections
Several pathogens have been associated with paediatric 
chronic urticaria, including viruses (e.g. Epstein-Barr 
virus), bacteria (mostly streptococci, staphylococci, 
Helicobacter pylori and Escherichia coli) and parasites 
(11, 13, 20–22).
In a study published more than 40 years ago, recurrent 
upper respiratory tract infections were described in 15 
out of 16 children with chronic urticaria (23). These data 
are in accordance with the current clinical experience 
of some working groups (13). Sackesen et al. (11) have 
documented infections in 6/17 (35%) children with 
 chronic urticaria. This is in clear contrast with the study 
by Kilic et al. (24), who found infections in none of the 
40 children with chronic urticaria, who were examined 
thoroughly for infectious diseases. 
Besides documenting infections, it is important to 
evaluate urticaria improvement or remission with the 
treatment of infections, which has been reported for 
respiratory and urinary infections (11, 13, 23). Gastro-
intestinal disease caused by H. pylori has also been 
linked to paediatric urticaria. Sackesen et al. (11) do-
cumented H. pylori infection in 3/17 (18%) children, 
all without gastrointestinal symptoms. One patient had 
urticaria remission after an eradication treatment. Other 
studies addressing childhood chronic urticaria have 
found 3/31 (10%), 2/93 (2%), and none out of 40 child-
ren infected with H. pylori (20, 22, 24). A case-control 
study regarding H. pylori infection in 167 children in 
Brazil found urticaria to be an independent variable 
associated with this bacterial infection (25).
Regarding parasites, a recent study including children 
has reported urticaria remission after the successful 
eradication of Blastocystis hominis infection with no re-
currence of symptoms in 1-year follow-up (15). Another 
study also found urticaria remission in 2/5 children with 
chronic urticaria after treatment for parasitic infestations, 
which was nevertheless not higher than the rate of ur-
ticaria remission in the remaining patients (57%) (21).
In order to estimate the role of different infections, 
and compare urticaria remission rates, a larger number 
of children should be evaluated in randomized con-
trolled trials. Moreover, data on this regard have to be 
carefully analysed, since the pathogenesis of chronic 
urticaria in a particular patient may be multifactorial 
and not only infectious (13).
Practical recommendation: Infectious symptoms and 
signs should be carefully assessed during anamnesis 
and physical examination and treated appropriately in 
all children with chronic urticaria. In addition, a more 
Table II. Underlying causes/eliciting triggers and general testing recommendations in childhood urticaria
Urticaria type Underlying causes/eliciting triggers/urticaria subtype General testing recommendations
Spontaneous acute 
urticaria
Infections (viral, bacterial or parasitic infections)
Hypersensitivity (e.g. foods, drugs)
Other (e.g. insect stings, inhalant allergens)
None recommended




Infections (viral, bacterial or parasitic infections)
Autoimmune conditions (e.g. thyroid autoimmunity, celiac 
disease, connective tissue disorders)
Other (e.g. hypersensitivity to foods, additives, drugs; 
malignancy)
Guided by suspected causes from anamnesis and physical 
examination




Other (heat contact, solar, delayed pressure, vibratory)
Perform physical urticaria subtype identification test with suspected 
eliciting trigger. If positive, determine the stimulation threshold
In dermographic and cold contact urticaria consider complete blood 
count with differential and erythrocyte sedimentation rate/C-
reactive protein. Rule out other diseases, if suspected
Other urticaria types Cholinergic
Contact
Other (exercise-induced, aquagenic)
Perform urticaria subtype identification test with suspected 
eliciting trigger. If positive, determine the stimulation threshold for 
cholinergic and exercise-induced urticaria
See text for details.
N.B. Different urticaria subtypes may coexist in the same child.
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thorough search for infectious agents may be advisable 
in those children with refractory chronic urticaria. 
Guide lines recommend a complete blood count with 
differential and erythrocyte sedimentation rate or C-
reactive protein as useful for a diagnostic approach in 
chronic spontaneous urticaria, which may highlight 
suspicion for underlying infections (Table II). 
Autoreactivity
Recent publications have highlighted the role of auto-
reactivity in childhood chronic spontaneous urticaria. 
Autoreactivity can be assessed in vivo by the autologous 
serum skin test (ASST). This test does not define, per 
se, autoimmune urticaria, which should include clinical, 
immunological and other laboratory criteria, currently a 
matter for analysis to be formally defined (26). Positive 
ASST indicates the presence of factors (which may 
include autoantibodies or others) in the patient’s own 
serum, responsible for the development of wheals. In 
order to demonstrate functional autoantibodies and their 
specificity, a basophil histamine release assay and an 
immunoassay (Western blot or enzyme linked immuno-
sorbent assay), respectively, should be performed (26).
Data analysis from some of the largest studies concer-
ning results of ASST in childhood chronic spontaneous 
urticaria, each testing >40 children, shows a frequency 
of positive ASST in 38–47% of these patients (20–22, 
27). These children with positive ASST had similar 
clinical characteristics to those with negative ASST. 
There were no differences in medication requirements 
or chronic urticaria remission between children with 
positive and negative ASST (20–22, 27).
The study conducted by Du Toit et al. (27) also detec-
ted autoantibodies to the IgE receptor in 37 of 78 (47%) 
tested children with chronic urticaria. This was similar 
to the previously published study by Brunetti et al. (20) 
(40%) testing a total of 52 children. Furthermore, Bru-
netti et al. demonstrated a positive correlation between 
a positive ASST result and histamine release. However, 
Du Toit et al. (27) could not find a significant correlation 
between the ASST result and the presence of histamine-
releasing factors or of autoantibodies to the IgE receptor.
Overall, the role of autoreactivity deserves additional 
analysis.
Practical recommendation: Current data do not support 
the routine use of the ASST in children with chronic ur-
ticaria, since, to date, it has not been proven to enhance 
the identification of an underlying cause or disease or 
to be useful in predicting urticaria severity, duration or 
the best therapeutic approach. 
Thyroid autoimmunity
Additional evidence supporting an autoimmune basis 
in chronic urticaria comes from its association with 
other autoimmune conditions, namely thyroid autoim-
munity (3). In a study by Caminiti et al. (28) conduc-
ted in Italy, 9 out of 95 (9.5%) children with chronic 
urticaria had anti-thyroid autoantibodies, 4 of them 
with Hashimoto’s disease. In contrast, Brunetti et al. 
(20) reported that none of the 93 studied children with 
chronic urticaria, also recruited from Italy, showed 
signs of thyroid autoimmunity. The reason for this 
difference may rely on the severity of urticaria, as all 
the patients included in the study by Caminiti et al. 
(28) had antihistamine-resistant chronic urticaria, with 
the need for frequent oral steroids for disease control. 
Thus, it is hypothesized that children with more severe 
or unresponsive to standard treatment chronic urticaria 
may have associated autoimmune conditions more 
frequently.
Other studies, each involving > 80 children with chro-
nic urticaria, have found increased levels of anti-thyroid 
antibodies in 1.1–4.3% of these patients (21, 22, 29). 
Thyroid abnormalities in childhood chronic urticaria 
deserve more investigation in future studies, also re-
garding the fact that thyroid autoimmunity prevalence 
differs in different populations.
Practical recommendation: For the present, it is con-
sensual that laboratory examinations for thyroid hormo-
nes or antibodies should not be performed on a routine 
basis, but only if the child’s personal or family history 
suggests thyroid dysfunction (Table II).
Other autoimmune conditions
Other autoimmune conditions have been reported in 
children with chronic urticaria, namely juvenile idio-
pathic arthritis, systemic lupus erythematosus, type 1 
diabetes and coeliac disease. From these, the role of 
coeliac disease is stressed, as it may be subclinical 
and has been suggested to cause chronic urticaria in 
some children rather than being simply an associated 
disease. This was supported by a study comparing 79 
children with refractory chronic spontaneous urticaria 
with 2,545 children with a negative clinical history for 
urticaria (28). Coeliac disease was found in 4 out of 79 
(5%) children with chronic spontaneous urticaria, sig-
nificantly more than in controls (0.67%). All 4 children 
had complete remission of urticaria within 5–10 weeks 
on a gluten-free diet. Other reports associating chronic 
urticaria with coeliac disease in children have been 
found. The vast majority of these children had urticaria 
remission after a gluten-free diet (30–32). This finding 
is worthy of further investigation, since it might suggest 
screening for coeliac disease in children with chronic 
urticaria, especially in refractory cases.
Practical recommendation: Coeliac disease and other 
autoimmune conditions should be considered, if sug-
gested by the patient’s history.
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Food hypersensitivity
IgE-mediated food allergy is very rarely the cause of 
chronic urticaria in children (21, 22, 27). Regarding 
food additives, a study conducted more than 10 years 
ago showed that 12/16 (75%) children with chronic 
urticaria went into remission under a stringently con-
trolled low-pseudoallergen diet for 3 weeks. Urticaria 
reappeared when the prohibited foods were reintrodu-
ced. Reactions occurred mainly to colouring agents 
and preservatives, but also to monosodium glutamate 
and a sweetener (saccharin/cyclamate) (33). Martino et 
al. (34) previously studied a total of 120 children with 
intermittent or recurrent urticaria. After a diet devoid of 
food additives and during a symptom-free period with-
out medication intake, children were orally challenged 
with 7 food additives. None reacted to placebo, while 
56 (46%) children had one or more positive challenges 
to food additives, evidencing urticaria. Colouring agents 
and preservatives were also relevant to the majority.
The so-called pseudoallergen-free diets may be 
beneficial to some patients. However, special care is 
required as these diets are usually very strict, many es-
sential foods being forbidden, and therefore potentially 
harmful for the child and consequently not advisable.
Practical recommendation: Suspected hypersensitivity 
to foods and food additives must be documented in a 
patient-tailored way in selected cases, guided by history. 
Ultimately, it should be confirmed by a supervised eli-
mination diet for at least 3 weeks (preferably dietician-
supervised to avoid dietary deficiencies) followed by 
oral challenge tests (adapted to the particular patient 
and suspected food/additive). 
Other precipitants
Recurrence of urticaria has also been described after 
drug intake in children with chronic urticaria, although 
this is not a commonly suspected precipitant in paedia-
tric studies (11, 22).
Occasional reports of paediatric malignancy associa-
ted with chronic urticaria in literature stress the need for 
a thorough history, physical examination and follow-
up (35, 36). There is no evidence supporting a screen 
for malignancies in children with chronic spontaneous 
urticaria (3).
Practical recommendation: Other possible triggers for 
urticaria should be carefully considered during anam-
nesis and physical examination. Extended testing is 
recommended, if suspected by history (Table II).
Physical urticaria
Physical triggers are the most commonly identified 
aetiology in childhood chronic urticaria (5, 6, 11, 37). 
Physical urticaria subtypes are described according to 
the eliciting trigger: cold contact, heat contact, solar, 
dermographic, delayed-pressure and vibratory urticaria 
(3). Dermographic and cold urticaria are highlighted 
mainly due to its frequency and potential severity, 
respectively.
Dermographic urticaria
Dermographic urticaria is elicited by mechanical shea-
ring forces (rubbing/scratching rapidly inducing wheals, 
typically without angioedema). Khakoo et al. (6) studied 
53 children with physical and other inducible urticaria 
types. Dermographic urticaria alone was diagnosed in 
38% of all cases. Together with cholinergic urticaria, 
alone or in mixed forms, it accounted for > 70% of all 
cases. Regarding a more general paediatric population, 
a study randomly selecting children from a healthcare 
centre in Spain has estimated a prevalence of 10% of 
dermographic urticaria among children (38).
It is important to clearly distinguish this condition 
from simple dermographism (i.e. wheal upon minimal 
friction without pruritus), which is more frequent and 
requires no investigation or treatment (39).
Dermographic urticaria is usually considered idiopa-
thic. However, it has also been described as secondary 
to infections, infestations, drugs or related to systemic 
mastocytosis.
Cold urticaria
This subtype is considered when cold (objects, air or 
fluids) induces immediate urticaria. Anaphylaxis due 
to cold exposure has been reported in up to 50% of 
children with this condition (40–42). While, in the vast 
majority, cold urticaria is idiopathic, there are secondary 
forms (43). These are more frequent due to infections 
(mostly documented association to viral infections) or 
cryoglobulinaemia (40, 42–44). Atypical cold urticaria 
forms have also been described, with immediate nega-
tive or uncharacteristic responses (such as systemic or 
prolonged reactions) to cold-stimulation testing, being 
either hereditary or acquired (43, 45).
Practical recommendation: Each physical urticaria sub-
type is diagnosed by performing specific testing (Table 
II) (3, 39). Specific tools have been validated for cold 
(Peltier element-based provocation device TempTest®) 
and dermographic (calibrated dermographometer) ur-
ticaria, which have also been tested on children (3, 39, 
46, 47). In dermographic and cold urticaria, extended 
testing for suspected causes or for differential diagnosis 
may be considered, according to history (Table II) (3).
When physical urticaria is diagnosed, avoidance of 
physical stimuli is crucial. Simple measures, such as 
avoiding tight-fitting or woollen clothing next to the skin 
of children with dermographic urticaria, may be use-
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ful. Exposure to cold environment or ingestion of cold 
foods, such as drinks or ice-cream, should be considered 
to prevent cold urticaria. Taking into account the risk for 
anaphylaxis and for drowning, aquatic activities should 
be banned in cold-induced systemic reactions (42, 48). 
Other urticaria types
Other inducible types of urticaria are taken into account: 
cholinergic, exercise-induced, contact, and aquagenic 
urticaria.
Cholinergic vs. exercise-induced urticaria
In the study by Khakoo et al. (6), the cholinergic sub-
type was found to be the second most common form. 
Cholinergic urticaria must be differentiated from the 
far less frequent exercise-induced urticaria. The former 
occurs within minutes after the elevation of the body 
temperature, regardless whether passive (hot shower) 
or active (exercise), whereas hot bath testing will not 
elicit exercise-induced urticaria (39, 49). Besides, in 
cholinergic urticaria, wheals typically have a diameter 
of less than 5 mm. Those associated with exercise-
induced urticaria are substantially larger, the evolution 
to anaphylaxis being frequent. Classic exercise-induced 
anaphylaxis has been predominantly described in young 
adults and adolescents, usually occurring within 30 min 
of exercising. It is typically preceded by cutaneous 
manifestations with a rapid progression to severe sys-
temic reaction (50–52). In some cases, symptoms only 
occur when exercise is preceded by food intake. This 
entity is designated as food-dependent exercise-induced 
anaphylaxis (FDEIA). FDEIA is usually associated with 
IgE-mediated hypersensitivity to food (52). Wheat is the 
most frequently associated culprit. Other foods such as 
distinct cereals, shellfish, nuts, vegetables, fresh fruits, 
milk and egg have been implicated (52). The intake 
of these foods is tolerated in the absence of exercise, 
distinguishing this syndrome from food allergy. The 
diagnostic approach includes an isolated suspected oral 
food challenge, an isolated exercise test (without food 
intake in the previous 4 h) and an exercise test after 
suspected food intake. The high risk of severe reactions 
must be carefully considered, the sensitivity of this 
combined test being only 70% (53). Specific-IgE to 
omega-5 gliadin, a major allergen in wheat-dependant 
exercise-induced anaphylaxis, has been shown to be 
useful for the diagnosis of this condition, possibly 
avoiding the need for a provocation test (54).
Contact urticaria
Contact urticaria involves immediate hypersensitivity 
reactions to exogenous proteins and chemicals (3, 55). 
Studies systematically addressing contact urticaria in 
children are scarce. Latex has been one of the main 
causes of immunological contact urticaria. It was an 
important issue in children with spina bifida or other 
conditions involving multiple chirurgical procedures 
with latex contact since early life. Fortunately, a de-
creased prevalence has been observed due to primary 
preventive measures (56). Oral and perioral urticaria 
occurring after the direct contact of the oral mucosa 
with food is a frequent manifestation of food allergy in 
children (19). A clinically-relevant cross-reactivity to 
pollen is common (pollen-fruit syndrome) (19). Contact 
urticaria may progress to systemic symptoms, which 
could be severe and life-threatening (55).
Aquagenic urticaria
Urticaria elicited by contact with water independent of 
temperature is a rarity, especially in children and is not 
discussed further.
Practical recommendation: In this category, each 
urticaria subtype implies specific testing according 
to the eliciting factor (Table II) (3, 39). Avoidance of 
triggers is essential. Regulating the bathing temperature 
is important in cholinergic urticaria. Exercise-induced 
urticaria/anaphylaxis may imply the avoidance of phy-
sical exercise or the ingestion of suspected food >4–6 h 
before exercise (53).
TREATMENT AIMED AT PROVIDINg SYMPTOM 
RELIEF 
Antihistamines: second generation
Antihistamines are used to inhibit the effect of mast 
cell and basophil mediators on the target tissue and to 
induce symptom relief. The use of second-generation 
H1-antihistamines (2ndGAH) at a standard dose in spon-
taneous and cold urticaria is the only therapeutic option 
with a strong recommendation from current guidelines 
(Table I) (2).
Cetirizine and its active enantiomer levocetirizine are 
the most comprehensively studied 2ndGAH in children 
with urticaria. Both drugs have been reported to sig-
nificantly reduce urticaria episodes, while being safe 
for children as young as 1–2 years old, evaluated in 
randomized double-blind placebo-controlled trials las-
ting 18 months (57–59). Additional evidence supports 
the use of other 2ndGAH, namely desloratadine, fexo-
fenadine and loratadine, approved for children in both 
Europe and the USA (60–64). However, randomized, 
double-blind, placebo-controlled studies evaluating 
2ndGAH in childhood acute and chronic urticaria are 
scarce, especially regarding children under the age of 
12 years. Dosage adjustments are required for the use 
of licensed antihistamine in children (Table III).
Guidelines for chronic urticaria recommend increa-
sing the dose of 2ndGAH up to 4-fold, as needed, to 
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provide symptom relief (2). However, this approach 
has not yet been validated in children (Table I) (60).
Given inter-patient variability as well as the possi-
bility of dissimilar in vivo H1-receptor antagonist po-
tency of each antihistamine, the change to an alternative 
2ndGAH may result in enhanced symptom relief (2, 
65–68).
Practical recommendation: Antihistamines (2ndGAH) 
are the mainstay of pharmacological treatment aimed 
at providing symptom relief (Table I). Posology adjust-
ments are required for the use of 2ndGAH in children 
(Table III).
Antihistamines: first generation
Contrary to recommendations, first-generation H1-anti-
histamines (1stGAH) are used in children despite their 
known adverse effects and the absence of satisfactory 
randomized, placebo-controlled trials to support their 
efficacy. Indeed, information on pharmacokinetics and 
pharmacodynamics in children is scarce for most of 
1stgAH (60). Unlike 2ndGAH, the unfavourable thera-
peutic index of 1stGAH has been well documented in 
children and must be considered. After standard doses 
of 1stGAH, there is potential sedation and impairment 
of alertness, cognition, learning, memory as well as 
psychomotor performance and behavioural changes (60, 
69). Infants and young children may show paradoxical 
excitation, irritability, hyperactivity, hallucinations and 
seizures, usually in overdose, which may be followed 
by coma and respiratory depression (60). Other adverse 
effects include sleep disruption, arrhythmias, dry mouth, 
constipation, urinary retention, increased appetite and 
weight gain. Furthermore, 1stGAH have been causally 
linked with deaths from accidental overdose and with 
homicide (60, 69).
Practical recommendation: The use of 1stGAH in child-
ren is strongly discouraged (Table I) (2, 69).
Further therapeutic options
There is a very significant lack of studies addres-
sing the efficacy and safety of other pharmacological 
therapeutic approaches in severe, refractory childhood 
urticaria cases. 
Montelukast is licensed for paediatric use, but there 
are very few studies assessing the effectiveness of ad-
ding montelukast systemic therapy to antihistamine 
treatment of urticaria in children (70).
Although there are successful case reports, greater 
studies to support the recommendation of other thera-
peutic options, including cyclosporine, immunoglobulin 
or omalizumab, in childhood refractory urticaria are 
missing (48, 71–75).
Corticosteroids can control urticaria effectively. How-
ever, the potential side-effects of chronic use restrict its 
application (2, 48). 
Other potentially relevant therapeutic options in selec-
ted cases include the induction of tolerance, which may 
be considered in some urticaria types such as cold and 
cholinergic urticaria (2). Cold tolerance treatment has 
been reported to be effective and well-tolerated by some 
Table III. Oral second-generation H1-antihistamines licensed for paediatric use (alphabetical order)a
Drug Form Daily dose for children Daily dose for adults
Bilastineb T  ≥ 12 years: 20 mg once a day 20 mg once a day
Cetirizinec S, T  2–5 year: 2.5 mg twice a day
 6–11 years: 5 mg twice a day
 ≥ 12 years: 10 mg once a day
10 mg once a day
Desloratadinec S, LYO, T  1–5 years: 1.25 mg once a day
 6–11 years: 2.5 mg once a day
 ≥ 12 years: 5 mg once a day
5 mg once a day
Ebastine S, LYO, T  2–5 years: 2.5 mg once a day
 6–11 years: 5 mg once a day
 ≥ 12 years: 10 mg once a day
10 mg once a day
20 mg once a dayd
Fexofenadinec T  6–11 years: 30 mg twice a dayd
 ≥ 12 years: 120 mgd or 180 mg once a day
120 mgd or 180 mg once a day
Levocetirizinec S, T  2–5 years: 1.25 mg twice a day
 ≥ 6 years: 5 mg once a day
5 mg once a day
Loratadine S, T  2–11 years: 5 mg once a day
 ≥ 12 years: 10 mg once a day
10 mg once a day
Mizolastine T  ≥ 12 years: 10 mg once a day 10 mg once a day
Rupatadineb T  ≥ 12 years: 10 mg once a day 10 mg once a day
aTopical antihistamines are not recommended for the treatment of urticaria, according to current guidelines. bAccepted European Medicines Agency 
paediatric investigation plan. cIn some countries, approved for the treatment of chronic idiopathic urticaria in infants > 6 months. dLicensed only for allergic 
rhinitis both in Germany and Portugal.
T: tablet; S: solution; LYO: lyophilisate/orodispersible tablet.
(N.B. This table is a summary based upon European Medicines Agency marketing authorization as well as that from authors’ national health authorities by 
May 2012. For country-specific information, national health authority recommendations should be observed.)
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motivated children (48). The risk of severe reactions due 
to cold exposure must, however, be considered.
Practical recommendation: In refractory cases, the 
physician must carefully assess the best therapeutic 
risk-benefit ratio of other therapeutic approaches for 
the particular child (Table I). Corticosteroids should 
be used only in selected severe cases and exacerbations 
and only for short periods (Table I). A poor response 
to therapy should also enforce a differential diagnosis. 
FOLLOW-UP AND PROgNOSIS
The monitoring of the physical, cholinergic and 
exercise-induced urticaria includes the threshold deter-
mination of the eliciting factors, since specific testing 
allows the estimation of disease activity (3, 39). For 
spontaneous urticaria, the Urticaria Activity Score based 
on the assessment of key urticaria symptoms (wheals 
and pruritus) is simple and suitable for disease activity 
evaluation in adult chronic urticaria patients (3, 76). 
Such a validated tool is missing for paediatric patients 
and would be very desirable.
Likewise, an urticaria-specific quality of life ques-
tionnaire for children and caregivers would be useful. 
Using Children’s Life Quality Index©, quality of life 
impairment in children with chronic urticaria has been 
considered higher than that experienced in the case of 
children with asthma or epilepsy (77). Chronic urticaria 
is known to significantly affect school performance, 
causing school absenteeism and parents taking days 
off work (78).
Regarding prognosis, acute urticaria is transient, re-
solving without any sequels in the vast majority of cases.
Chronic spontaneous urticaria has usually been consi-
dered to have an overall long-term favourable prognosis. 
It is rarely associated with severe or life-threatening 
diseases or the development of serious illness. Sahiner 
et al. (22) reported urticaria remission in 16.5% of the 
82 evaluated children after 1 year. After 3 years, 38.8% 
of the children were urticaria-free and after 5 years, it 
had resolved in half of the cases, without any relapse or 
identified sequel. In univariate analysis, the coexistence 
of female gender and being older than 10 years predicted 
an unfavourable prognosis. However, in multivariate 
analysis, age, gender, the presence of angioedema or 
other allergic diseases, autoimmunity family history, 
ASST positivity or abnormal laboratory results did not 
predict the prognosis.
Physical and other urticaria types may have a worse 
prognosis. In the study by Khakoo et al. (6), the number 
of children becoming urticaria free was 11.6% after 1 
year and 38.4% after 5 years. In a univariate analysis, 
a history of other allergic conditions in the child and 
more frequent urticaria episodes were associated with 
having a greater risk of non-remission. No significant 
difference in the age of onset of urticaria and duration 
of individual bouts was noted between the remission 
and non-remission groups.
CONCLUSION
Urticaria is common in children, being a frequent 
reason for doctors’ visits. Most paediatric cases of ur-
ticaria are acute, i.e. transient by definition, and resolve 
without sequel. In these cases, after an accurate clinical 
diagnosis, symptom relief therapy with 2ndGAH and no 
extended testing are recommended.
In chronic urticaria forms, appropriate testing should 
be guided by the child’s medical history. In these cases, 
especially in refractory urticaria, the important gap in 
medical knowledge regarding documented causes needs 
to be addressed. 
Another unmet need relates to formal evidence sup-
porting current therapeutic approaches in children with 
urticaria. The first-line antihistamine therapy lacks 
randomized controlled trials and the need for research 
addressing further therapeutic options in children with 
refractory urticaria is imperative.
Current knowledge on childhood urticaria requires the 
physician to be focused. A thorough anamnesis and a 
systematic, comprehensive physical examination are of 
utmost importance for an appropriate diagnosis. Further-
more, reasonable testing and subsequent effective and 
safe therapeutic decisions are required, aiming at the 
desirable goal of the child’s wellbeing.
The authors declare no conflicts of interest.
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